InvestSMART

Orthocell Limited (ASX:OCC)

ALERT: Price-sensitive ASX Announcement for OCC
Current share price for OCC : $0.690 -0.155 (-18.34%)+
Announcement
Release
13 Jul 2026 8:53AM
Price at Release
$0.845
Full Release
download
Summary
Orthocell Limited has reported a strong quarterly performance for the period ending 30 June 2026, with record revenue of $3.8 million for the June quarter and $13.2 million for FY2026. This growth is attributed to the increased adoption of Remplir™ in Australia and the United States, as well as expansion into new international markets. The company maintains a robust financial position with $44.1 million in available funds, supporting its strategic plans without the need for additional funding. Orthocell continues to focus on commercial expansion, optimizing production efficiencies, and expanding its manufacturing capacity. The company is also progressing with regulatory approvals in the UK and EU, anticipating a significant market opportunity for its nerve repair products in these regions.
Key Points
  • Record revenue of $3.8 million for June quarter.
  • FY2026 revenue reached $13.2 million, a 44% increase from the previous year.
  • Strong financial position with $44.1 million in funds.
  • Continued global expansion and adoption of Remplir™ and Striate+™.
  • U.S. generated $0.33 million from Remplir sales in the last quarter.
  • Strategic growth initiatives in UK/EU markets.
  • Focused on production efficiency and manufacturing capacity expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.